Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
Cingulate Inc. (NASDAQ: CING) has appointed Nilay Patel, JD as Chief Legal Officer as the company prepares to submit a New Drug Application (NDA) for its ADHD treatment CTx-1301. Patel brings over 20 years of pharmaceutical industry experience, most recently serving as Chief Legal Officer at Ironshore Pharmaceuticals.
The appointment comes at a crucial time as Cingulate plans to file its NDA for CTx-1301 (dexmethylphenidate HCl) in the coming weeks. The company granted Patel stock options for 30,000 shares at $4.51 per share, vesting over four years with 25% vesting after the first year and the remainder monthly over 36 months.
Cingulate Inc. (NASDAQ: CING) ha nominato Nilay Patel, JD come Chief Legal Officer mentre l'azienda si prepara a presentare una New Drug Application (NDA) per il suo trattamento ADHD, CTx-1301. Patel vanta oltre 20 anni di esperienza nel settore farmaceutico, avendo ricoperto recentemente il ruolo di Chief Legal Officer presso Ironshore Pharmaceuticals.
La nomina avviene in un momento cruciale, poiché Cingulate intende presentare la sua NDA per CTx-1301 (dexmetilfenidato HCl) nelle prossime settimane. L'azienda ha concesso a Patel opzioni su azioni per 30.000 titoli a 4,51 dollari per azione, con maturazione in quattro anni, di cui il 25% dopo il primo anno e il resto mensilmente nei successivi 36 mesi.
Cingulate Inc. (NASDAQ: CING) ha nombrado a Nilay Patel, JD como Chief Legal Officer mientras la compañía se prepara para presentar una Solicitud de Nuevo Fármaco (NDA) para su tratamiento de TDAH, CTx-1301. Patel aporta más de 20 años de experiencia en la industria farmacéutica, habiendo desempeñado recientemente el cargo de Chief Legal Officer en Ironshore Pharmaceuticals.
El nombramiento llega en un momento crucial, ya que Cingulate planea presentar su NDA para CTx-1301 (clorhidrato de dexmetilfenidato) en las próximas semanas. La empresa otorgó a Patel opciones sobre 30,000 acciones a $4.51 por acción, con un periodo de adquisición de derechos de cuatro años, con un 25% al cabo del primer año y el resto mensualmente durante los siguientes 36 meses.
Cingulate Inc. (NASDAQ: CING)는 ADHD 치료제 CTx-1301의 신약 신청서(NDA)를 제출할 준비를 하면서 Nilay Patel, JD를 최고법률책임자(Chief Legal Officer)로 임명했습니다. Patel은 20년 이상의 제약 산업 경력을 보유하고 있으며, 최근에는 Ironshore Pharmaceuticals에서 최고법률책임자로 근무했습니다.
이 임명은 Cingulate가 향후 몇 주 내에 CTx-1301(덱스메틸페니데이트 염산염)의 NDA를 제출할 계획인 중요한 시기에 이루어졌습니다. 회사는 Patel에게 주당 4.51달러에 30,000주에 대한 스톡옵션을 부여했으며, 4년 동안 권리가 취득되며 첫 해에 25%, 나머지는 36개월 동안 매월 분할 취득됩니다.
Cingulate Inc. (NASDAQ: CING) a nommé Nilay Patel, JD au poste de Chief Legal Officer alors que la société se prépare à soumettre une demande d’autorisation de mise sur le marché (NDA) pour son traitement du TDAH, CTx-1301. Patel apporte plus de 20 ans d’expérience dans l’industrie pharmaceutique, ayant récemment occupé le poste de Chief Legal Officer chez Ironshore Pharmaceuticals.
Cette nomination intervient à un moment crucial, car Cingulate prévoit de déposer sa NDA pour CTx-1301 (chlorhydrate de dexméthylphénidate) dans les semaines à venir. La société a accordé à Patel des options d’achat de 30 000 actions à 4,51 $ par action, acquises sur quatre ans, avec 25 % acquis après la première année et le reste mensuellement sur les 36 mois suivants.
Cingulate Inc. (NASDAQ: CING) hat Nilay Patel, JD zum Chief Legal Officer ernannt, während das Unternehmen sich darauf vorbereitet, einen New Drug Application (NDA) für seine ADHS-Behandlung CTx-1301 einzureichen. Patel bringt über 20 Jahre Erfahrung in der Pharmaindustrie mit und war zuletzt als Chief Legal Officer bei Ironshore Pharmaceuticals tätig.
Die Ernennung erfolgt zu einem entscheidenden Zeitpunkt, da Cingulate plant, in den kommenden Wochen seine NDA für CTx-1301 (Dexmethylphenidat HCl) einzureichen. Das Unternehmen gewährte Patel Aktienoptionen für 30.000 Aktien zu 4,51 USD pro Aktie, die über vier Jahre mit 25 % nach dem ersten Jahr und dem Rest monatlich über 36 Monate vesten.
- Strategic hire with extensive ADHD market and pharmaceutical legal expertise
- Imminent FDA filing for lead ADHD drug CTx-1301
- Appointment strengthens leadership team ahead of potential commercialization phase
- Additional stock-based compensation may lead to dilution
Pharma Vet brings 20+ years of Legal, Compliance, and Commercialization Expertise as Company prepares ADHD Drug Filing
KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has named Nilay Patel, JD, as Chief Legal Officer. Patel’s appointment comes as Cingulate plans to submit a new drug application to the FDA in coming weeks for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Mr. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across every stage of drug development, launch, and commercialization. He most recently served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary at Ironshore Pharmaceuticals.
“We are pleased to welcome Nilay Patel to Cingulate at such a pivotal time in our company’s progression,” said Shane J. Schaffer, Chairman and CEO of Cingulate. “As we file to seek approval for CTx-1301, Nilay brings an extensive knowledge of the ADHD landscape and a rare blend of deep legal expertise, operational insight, and proven leadership in navigating the complexities of pharmaceutical commercialization.”
Before joining Ironshore, Mr. Patel held senior legal roles at Grifols, where he served as Assistant General Counsel for the company’s U.S. Bioscience division, and at Life Sciences Law PLLC, where he represented both emerging biotech firms and global pharmaceutical clients in licensing, mergers and acquisitions, and intellectual property matters.
“I’m honored to join Cingulate at an exciting and inflectional stage in its growth,” Patel stated. “I was drawn to Cingulate because of its seasoned management team and innovative approach to addressing long-standing challenges in ADHD treatment through science-driven, patient-focused solutions, and I look forward to advancing the company’s vision and long-term success as we move closer to commercialization.”
On July 8, 2025, the Company granted non-qualified stock options to Nilay Patel to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share of
About Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., over 20 million patients have been diagnosed with ADHD. Among this group, 12 million are adults and over 8 million are under the age of 17. According to the CDC, just 53.6 percent of all children and teens with ADHD reported they were actively treating their symptoms with medication in 2022, with 65–90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Current market trends demonstrate that adult ADHD prevalence is larger and growing faster than the child and adolescent segments combined.
About CTx-1301
Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. While stimulants are the gold standard of ADHD treatment due to their efficacy and safety, the long-standing challenge continues to be providing patients with an entire active-day duration of action. CTx-1301 is designed to precisely deliver three releases of medication at the predefined time, ratio, and style of release to optimize patient care in one tablet. The result is a rapid onset and entire active-day efficacy, with the third dose being released around the time when other extended-release stimulant products begin to wear off.
About Precision Timed Release™ (PTR™) Platform Technology
Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the core tablet. The EBL formulation, OralogiK™, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition to Anxiety and ADHD where one or more active pharmaceutical ingredients need to be delivered several times a day at specific, predefined time intervals and released in a manner that would offer significant improvement over existing therapies. To see Cingulate’s PTR Platform, click here.
About Cingulate Inc.
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit Cingulate.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our other filings with the SEC. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
Investor & Media Relations:
Thomas Dalton
Vice President, Corporate Communications, Cingulate
tdalton@cingulate.com
(913) 942-2301
FAQ
Who is Nilay Patel and what is his role at Cingulate (NASDAQ: CING)?
What is CTx-1301 and when will Cingulate submit its FDA application?
What compensation package was offered to Nilay Patel at Cingulate?
What is Cingulate's Precision Timed Release™ (PTR™) technology?
What was Nilay Patel's previous experience before joining Cingulate?
